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Abstract
In the past few decades, an emerging drug delivery system that came into light is transder-
mal drug delivery system. It has become the talk of the town in the field of drug delivery
because of its better and easy accessibility. Though it is one of the attractive routes, trans-
port of drug through the skin has remained a challenge. To overcome the challenge,
vesicular system has been adopted so as to have better skin permeation of bioactive agents.
Vesicular system like liposome has shown inefficiency to cross the layers of skin. Then
transethosomes and nanoethosomes are employed for delivering drug into the deeper
layer of skin. Nanoethosomes and transethosomes have same composition that is water,
ethanol and phospholipid. Transethosome contains edge activator additionally. Due to the
presence of ethanol and edge activator, it displayed enhanced skin permeation. Vesicular
system gives a better patient compliance, being a non-invasive method of drug administra-
tion. In this chapter, we attempted to provide brief information about methods of prepara-
tion, characterization and pharmaceutical uses of nanoethosomes and transethosomes.
Keywords: transdermal, transethosomes, nanoethosomes
1. Introduction
In last few decades many significant advancement in the field of drug delivery technology
have been made. This advancement took place as there was no remarkable growth in develop-
ing new drug entities. Drug delivery emerged as a branch of science which comprises of
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biopharmaceutics and pharmacokinetics. Drug delivery technology is accepted as it imparts
therapeutic as well as economical values to the health care products. The above said character-
istic of drug delivery technology helps the old drugs to stand the competition of growing
market. Drug delivery enhances the efficacy of drugs through controlled release by consider-
ing the factors like carrier system, route of administration and target of drug action. Drug
delivery system improves patient compliance, therapeutic index and bioavailability [1].
In present scenario researchers are working on delivering the active pharmaceutical ingredient
through transdermal route but still the effective delivery of drug through the said route is
challenging. Transdermal drug delivery system originated in the year 1950 in U.S. In transder-
mal system drug permeate from the outer layer of skin to the blood stream through various
layers of skin [2]. Transdermal drug delivery system is advantageous over traditional method.
Drug administered through transdermal drug delivery system does not pass through GI Tract
so are not exposed to degradation in the gut. As transdermal system delivers drug directly into
blood stream through layers of skin, so drugs bypasses pre-systemic metabolism. Transdermal
system is most suitable for drugs with short half life and narrow therapeutic range. The system
helps in maintaining controlled level of plasma, in case of toxicity drug administration can be
easily stopped. Few disadvantages are also attached to this system, such as drugs requiring
blood volume cannot be administered [3–7]. Due the patches and the adhesive used in it, few
recipients may experience skin irritation. For some section of patients it may not be economi-
cal. In the process of developing transdermal drug delivery system few basic areas has to be
considered such as drug’s bioactivity, the characteristics of skin, formulation employed, adhe-
sive to be used and the design of the system. Permeation of drug through skin is dependent on
factors like structure of skin and properties associated with it, the physicochemical property of
the penetration molecule in relationship with the skin and lastly the system that carries the
drug to the skin for penetration [8–10].
For overcoming the limitation of barrier function of skin some methods are undertaken such as
iontophoresis, sonophoresis, electrophoresis along with micro-invasive techniques, vesicular
system and employment of permeation enhancers [11, 12]. Transdermal system of drug delivery
transports bioactive agents directly into blood stream. Transdermal system has many benefits
like it bypasses first pass metabolism, it ensures better patient compliance and with this system
there is mere chances of any kind of tissue injury. Currently vesicular system is mostly studied
approach for transdermal drug delivery system. Vesicular system contains vesicles which are
composed of colloids with hydrophilic and amphiphilic groups. Hydrophilic part makes the core
and it is guarded by amphiphilic part in a bilayer effusion. The vesicular system act as a carrier
for drugs which may be hydrophilic, lipophilic or amphiphilic. The vesicles have the ability of
encapsulating the said drug types. Factors such as size, lamellarity, thermodynamic phase,
surface charge are determinant of the efficiency of vesicular system as carrier [13].
Presently various type of vesicular carrier systems are available such as liposomes, ethosomes,
transferosomes, niosomes, transethosomes etc. (Figure 1). All of them have their particular
merits and demerits. There is not a single vesicular carrier that can fulfill all the criteria of drug
delivery. In this chapter we are mainly focus on transethosomes and nanoethosomes vesicular
carrier system.
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2. Transethosomes
Liposomes, which are conventional lipid-based vesicular system, are not capable of crossing
the stratum corneum. As they exhibit low permeation into deeper layer of skin, eventually they
get accumulated on superior layer of stratum corneum. To improve the skin permeation,
liposomes are added with edge activators like Span 80, Span 25, Tween 80, sodium cholate
and are named as transferosomes. Transferosomes enhances skin permeation due to their
deformable ability but they are unable to penetrate deep into the stratum corneum. Another
vesicular system called ethosomes is also available. Ethosomes are composed of phospholipid,
ethanol and water (Table 1). Due to presence of ethanol the intercellular space between the
corneocytes increases which increase the permeation [14–16].
Transethosomes are the combination of transferosome and ethosomes. Transferosomes shows
both the quality of becoming deformable and skin permeation. This vesicular system was
introduced in the year 2012 by Song et al. Transethosomes can be taken by topical as well as
Figure 1. Schematic illustration of a panel of lipid-based nanocarrier transdermal delivery systems.
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systemic route. Drugs ranging from low molecular weight to high molecular weight can easily
be entrapped by this system. As the bioactive agent is protected due to encapsulation, so it
releases its content in a very slow and gradual manner. Due to their biodegradable and
biocompatible nature, it shows highly efficient entrapment ability. Its preparation does not
require any undue pharmaceutical additives and no tedious process is involved in it [15–17].
3. Nanoethosomes
Ethosomes are non-invasive carriers that assist the bioactive agents to penetrate deep into the
layers of skin or into the blood stream [18]. This is a modified version of liposomal carrier
system. They contains lipid vesicle along with water and ethanol. Ethosome was developed in
the year 1996 by Touitou [19]. Ethosomes are known to release the entrapped bioactive agents
in a constant and gradual manner. Ethosomes comes in various size. Ethosomes of nanometer
size are called nanoethosomes. Presence of high content of ethanol imparts a negative charge
on surface of vesicles which promotes reduction of its size [20]. Due to smaller size, nano-
ethosomes easily penetrate through the intercellular space [6].
4. Advantages and disadvantages of vesicular carriers
Many vesicular formulations for drug administration through parenteral, topical as well as
oral route have been developed. Vesicular drugs provides advantages like convenience, safer
way of drug administration and most importantly it provides a protection for the active
constituent in in-vivo condition from premature degradation. In addition to the said advan-
tages vesicular carriers makes it possible to release encapsulated molecule in sustained and
controlled manner. Due to this pattern of release it becomes easy to ensure targeted delivery of
drug to the target tissues. Challenges like pre-systemic metabolism, frequent dosing, and
variation in GI absorption of drug can be overcome by vesicular carriers. Vesicular carriers
reduce the dosing frequency due to which the cost to the patient decreases and ensures better
S. No. Additives Liposomes Ethosomes Transethosomes Examples Uses
1. Phospholipid Present Present Present Soya phosphatidyl
choline
Vesicle forming component
2. Polyglycol Absent Present Present Propylene glycol Skin penetration enhancer
3. Alcohol Absent Present Present Ethanol Softness for vesicle
membrane
4 Cholesterol Present Present Present cholesterol Stability provider to vesicle
membrane
5. Vehicle Present Present Present Carbopol D934 Gel former
6. Surfactant Absent Absent Present Sodium cholate Edge activator
Table 1. Composition of different lipid vesicular carrier system.
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patient compliance. Vesicular carrier increases the bioavailability as it enhances the permeation
of drug through biological carriers. Only disadvantage associated with vesicular carrier is that
few patients reported symptoms of dermatitis.
4.1. Advantages and disadvantages of transethosomes
Advantages of transethosomes are that it provides semisolid dosage form for administration
which gives a better patient compliance. Transethosomes ensures an enhanced permeation of
drug through skin. It bypasses presystemic metabolism. Few disadvantages of transethosomes
are like dermatitis, allergic reaction or skin irritation in some patients. Some product gets lost
as it is transferred from alcoholic media to aqueous media [21, 22].
4.2. Advantages and disadvantages of nanoethosomes
Nanoethosomes as a carrier makes it possible to deliver large molecules like proteins. The
material used to prepare nanoethosomes is non-toxic, so it is not at all harmful for the recipi-
ent. As it is easy to use, so it provides better patient compliance. As compared to methods like
phonophoresis, iontophoresis it is simple method of drug delivery. Few disadvantages are also
associated with nanoethosomes such as it does not provide a rapid bolus drug input. To gain
entry into blood circulation the drug has to be soluble in both lipophilic and aqueous phase.
Adhesives used in nanoethosomes may not adhere on the skin of every single patient. A
particular molecular size of drug can be can be delivered by this system. It may not be
economical for certain segment of patients [23–25].
S.
No.
Carriers/method Advantage Disadvantage
1. Liposomes Phospholipid vesicle, biocompatible Less skin penetration less stable
2. Physical methods,
e.g., iontophoresis
Increase penetration of intermediate size charged
molecule
Only for charged drugs, transfer
efficiency is low (less than 10%)
3. Niosomes Non-ionic surfactants vesicles Less skin penetration easy handling
but will not reach up to deeper skin
layer
4. Transferosomes
and
protransferosomes
More stable, high penetration due to high deformability,
biocompatible and biodegradable, suitable for both low
and high molecular weight and also for lipophilic as well
as hydrophilic drugs and reach up to deeper skin layers.
None, but for some limitations
5. Transethosomes • Enhanced drug permeation through skin for
transdermal drug delivery.
• Raw material in the formulation is non toxic in
nature.
• More stable
• The transethosomal drug is administrated in a
semisolid form.
• Avoidance of first pass metabolism
• Biocompatible and Biodegradable
• Product loss during transfer
from alcoholic and water
media.
• Skin irritation or allergic reac-
tion on contact dermatitis.
• Unsuccessful vesicle forma-
tion can Coalesce
transethosomes.
Table 2. Comparison with other vesicular systems with their advantages and disadvantages.
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4.3. Challenges of vesicular carriers
Though vesicular carriers are becoming popular day by day but due to chemical reactions like
oxidation and hydrolysis of the phospholipid component of vesicular carrier, its stability is a
matter of concern. The physical and chemical instability can be seen by events like leakage of
encapsulated drug and change in vesicle size which takes place due to fusion and aggregation.
4.4. Comparison with different vesicular carriers
The comparison of nanoethosomes and transethosome with other vesicular carriers are
described in Table 2.
5. Penetration mechanisms for ethanol-based vesicular carriers
5.1. Ethanol effect on skin
Nanoethosomes and transethosomes contains around 20–50% of ethanol [26]. The action of
ethanol on the lipid layer is shown in Figure 2with comparison to the lipid layer where there is
no ethanol present. Figure 2B is showing void space is created and filled with ethanol that in
turn increased area per lipid molecule [27]. X-ray diffraction shows that the lipid bilayer has
interdigitated Membrane leaflet which eventually leads to thinner membrane when ethanol
comes in contact with the lipid bilayer. As the surface density of lipid decreases the bilayer gets
thinner which leads to membrane distention. Due to presence of alcohol at the surface the
change in membrane shape get accelerated. Chanturiya et al. experimentally proved that
alcohol promote fusion of discontinuous membrane by breaking the single layer continuity.
This study do not confirm about alcohol accelerating post fusion membrane distention [28].
The result that comes up from this demonstration is that presence of ethanol can bring about
Figure 2. Schematic representation of ethanol’s presence and absence on the bilayer lipid membrane: (A) representation
of bilayer lipid membrane structure in the absence of ethanol; (B) presence of ethanol molecule is being represented as
gray and red dots in the lipid bilayer membrane which partition into glycerol backbone and a hydrophilic head resulting
in an increase in area per lipid molecule. (B) Also shows small leaflet interdigitation by representing the membrane
relatively thinner as compared to (A) that shows the effect of presence of ethanol in (B).
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alteration in rate of change in shape by membrane in an exocytosis manner. In this demonstra-
tion the concentration of alcohol is quite higher as compared to that which is found in the
blood in case of intoxication. Ethanol does accumulate in some region of body such as stria-
tum, brain to an extent of three times of the level that is found in blood. Clearance from alcohol
from striatum is relatively slower s compared to other region of body. This characteristic may
affect chronic alcoholics during an event of binge drinking as the kinetics of neurotransmission
may have an implication of the said characteristics [29].
5.2. Mechanism of skin penetration through vesicular carrier
Vesicular system assists in transdermal drug delivery of molecule either by enhancing penetra-
tion of free drug component or permeation is enhanced by the component of vesicles. In some
cases the transdermal drug delivery takes place by intact vesicle penetration into the skin and
then through it. Vesicle get adsorb and fused with the stratum and assist the transdermal drug
delivery. Ethanol a component in ethosomes and nanoethosomes act as a great permeation
enhancer as it fluidizes membranous lipid bilayer along with the lipid present in stratum
corneum. Liposomes contain phosphatidyl choline which is tightly packed as compared to
ethosomes or nano-ethosomes where phosphatidyl choline is loosely packed. Nano ethosomal
vesicles have more flexibility as compared to liposomes. Stratum corneum composed of com-
pactly packed phospholipid, when ethanol comes in contact with it disrupts the compact pack-
ing of phospholipid and fluidizes the lipid layer. This fluidization of lipid layer is the mechanism
through which drug delivery by nano-ethosomes occurs. E. Touitou et al. has carried out DSC
studies for ethosomal formulation which contains 30% ethanol, 5% phospholipid and liposomes
were prepared without ethanol. An investigation is carried out by M.M.A Elsayed et al. to prove
that the basic mechanism of skin delivery of drug is enhancement of permeation by ethanol and
flexible nature of vesicles. The investigation focused on the in-vitro profile of drug outside the
vesicles, drug inside the vesicle and drug on both side of vesicle. Out of the four the formulations
the drug which was present inside the vesicular carrier displayed enhanced permeation then the
remaining two formulations. From this it can be concluded that presence of ethanol is not major
factor of permeation, if it would have been the case then drug outside the vesicle would have
shown better permeation. This also suggests that the deformable nature of vesicle assist in
enhanced penetration and drug delivery of drug. Godin and Touitou [30] proved vesicle adsorp-
tion to the skin and fusion of vesicular layer with stratum corneum of skin. It is observed that the
drug present in liposomal preparation is unable to penetrate into skin although the preparation
gets adsorbed to the membrane. In case of ethosomal preparation the ethanol present in it gets
intercalated on lipid present in stratum corneum which results in increase in membrane perme-
ability. Ethosomes are flexible and after fusion with the membrane they successfully deliver the
drug inside the cells [31]. The main parameter that defines the movement of transfersomes across
the cutaneous is extent of flexibility and partition coefficient. The passage of transferosomes
through the stratum corneum layer is governed by hydration force. The fluid content of stratum
corneum is lower than other layer of skin due to which fluid gradient created. Cevc et al.
explained the passage through skin by osmotic strength theory [14]. The active ingredient
can easily release in stratum corneum and diffuse through different layer of skin and reaches
blood circulation. Transferosomes pass through the intercellular space of stratum corneum by
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deforming itself. No studies reported that transferosomes can permeate through the skinwithout
altering its shape. The vesicular carrier transethosome makes its pathway through the stratum
corneum into the deep skin layer by adhering to lipid lamella after interacting with the disturbed
layer of stratum corneum. The presence of ethanol and edge activator in vesicles enhances its
flexibility and fluidity and due this kind of elastic nature, vesicles can easily pass through narrow
intercellular pathway. The permeation mechanism of different type of vesicular carriers is
explained in Figure 3.
6. Method of preparation
There are four methods of preparation for nanoethosomes and transethosomes which are
explain in here.
6.1. Preparation by cold method
In this method, ethanol is taken and to it phospholipid is added then by constant stirring it is
dissolved at room temperature. Then to this solution propylene glycol is added and stirred
vigorously. Then the solution mixture is heated up to a temperature of 30C. Simultaneously on
other hand water is being heated with up to a temperature of 30C. Water and ethanol both
solvents are used so that drug according to its affinity can dissolve in either of them. Stirring is
continued to next 5 minutes. Then the suspension obtained is cooled down at maintained at room
temperature. In the final step, by employing methods like extrusion or sonication, the vesicle size
can be adjusted. Then the prepared ethosomal vesicles are kept in refrigerator for storage [32, 33].
6.2. Preparation by hot method
In hot method, a dispersion of phospholipid and water is subjected to heating at a temperature
of 40C. The step of heating at the same temperature is continued till colloidal solution is
Figure 3. Schematic representation of the main permeation mechanisms of lipid-based vesicles.
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formed. Simultaneously in another vessel two more solvent namely glycol and ethanol is
added and heated at a 40C. When both mixtures steadily attain a temperature of 40C then
to the aqueous phase the organic phase is added. Then stirring is done up to next 5 minutes
and the obtained vesicle suspension is cooled down to room temperature. Depending on the
ability and affinity of drug to bind with hydrophilic and hydrophobic solvent, it either gets
dissolved in water or in ethanol. The required size of ethosome vesicles can be easily prepared
by using methods like extrusion or sonication [6].
6.3. Preparation by classical method
Here in this method, a mixture of ethanol, active medicaments and phospholipid is taken in
such way that the active medicament and phospholipid get dissolved in ethanol. Then the
solution mixture is heated by using a water bath at a temperature of about 30  1C. In the
next step to solution mixture double distilled water is added with continuous stirring at a
speed of 700 rpm. Then with the help of hand extruder, the obtained vesicles are homogenized
for three cycles using polycarbonate membrane [34].
6.4. Preparation by mechanical dispersion method
In this method a mixture of chloroform and ethanol is taken in a round bottom flask (RBF). To
the round bottom flask soya phosphatidylcholine is added and made to dissolve in the chloro-
form and ethanol mixture. By using rotary vacuum evaporator organic solvent is removed. This
step is carried out at a temperature that is above the lipid transition temperature. The main
purpose of maintaining that temperature is that at the said temperature a thin lipid film gets
deposited on the surface of a round bottom flask. Then the round bottom flask is kept overnight
so that trace of solvent can be obtained from the lipid film that got deposited on the round
bottom flask. Then hydroethanol hydration is being done by simply rotating round bottom flask
at the required temperature by employing different concentration of drug mixture [35].
7. Evaluation parameters of vesicular carriers
7.1. Morphology
Morphology defined as study of shape and size of vesicular carriers. Generally vesicular
carriers are regular spherical in shape and they are physically soft and flexible and core is
enclosed. On the basis of formulation, vesicular carrier may be small, unilamellar or
multilamellar. With the help of microscope morphology of vesicular carrier is studied. As most
of the vesicles are nano-sized so to view the morphology scanning electron microscopy is used.
In addition to identification study, morphology also explains the detection the pattern of
packing of particles and aggregation [36].
7.2. Particle size and size distribution
As smaller size increases the efficiency of drug delivery to the desired site, vesicles in the
vesicular carriers are of nanometer to micrometer range. Uniform size is major factor to
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consider and it can be achieved depending on instrumentation and formulation procedures.
Nanosizers are employed to measure the size and size distribution of vesicular carriers. Photon
correlation spectroscopy is also used for determination of particle size [18].
7.3. Zeta potential
Distribution of charge on the surface of vesicular carrier is expressed by zeta potential.
The presence of charge on the surface of nanoparticle is a major determinant of stability of
the product. The presence of negative and positive charge on vesicular carrier depends upon
the excipient used in the formulation. Zeta potential can be defined as the degree of electro-
static repulsion and attraction in colloidal dispersion. Zeta potential provides information
regarding every components of formulation and interaction among them. It also gives
information regarding surface chemistry. Zeta potential is determining factor for stability of
colloidal dispersion system. It also determines the interaction between vesicles and mem-
brane [37, 38].
7.4. Drug content
To ascertain whether the preparation content the required active ingredient in required
amount in the vesicles, the vesicles are lyses so that the content is released. The released
content is put into the solution then the solution is subjected to spectrophotometric analysis
or chromatographic assay. Lysis of vesicles is done by solvents like isopropylalcohol, metha-
nol, etc. [39].
7.5. Loading capacity, encapsulation efficiency, and vesicle yield
To have proper information about the drug that is actually trapped in the vesicles, entrapment
is determined. For determination of entrapment, from the formed vesicles unentrapped drug is
separated. Separation is done either by elution method using elution technique by the help of
suitable column or by simply by the method of ultracentrifugation. Centrifugation is supposed
to be done in such a controlled speed and temperature so that the vesicles do not get ruptured
during the process. At end of centrifugation the supernatant produced is separated from the
vesicles. Then the vesicles are treated with solvent likes triton-X. 2-propanol so that it get lysed
then drug content is subjected to UV vis spectroscopy, the amount of drug entrapped is
calculated [40]. The encapsulation efficiency (EE), Loading capacity (LC) and Vesicle Yield are
calculated by the following formula’s.
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Where Ao is the initial amount of the drug used, Au is the nonencapsulated drug, W is the
amount of lipid material used in the vesicular formulation and Av is the amount of vesicular
carrier produced [41].
7.6. Drug release and biophysical interactions
Drug release is dependent on many factors such as the additives used in formulation and also
the physiological condition at the site of administration. As we can consider when the particle
size is relatively larger and the vesicular carriers the non-flexible then their permeation across
the biological membrane is hampered. Every single body part possess its particular pH, if the
formulation that has to be administered in that area is in that pH range then physiological
functioning is not affected but in case the formulation has pH different from the physiological
pH of concerned area then physiological condition would get affected. pH can cause ionization
of drugs that can result in inability of the drug to pass through the biological barrier [42, 43].
7.7. Stability
The stability of the preparation can estimate by ensuring whether there is any change in vesicle
size. When stability is concerned, it is believed that homogeneous preparation is more stable as
compared to heterogeneous ones. Another way of determining the stability of preparation is to
study its membrane stability and molecular arrangement by X-ray scattering or differential
scanning method. Study of particle size is just considered as a quality control test not a test to
ascertain the internal stability of preparation. This conclusion is made as it is seen in properly
lyophilized liposome, where particle size is stable but additive like cryoprotectant interfere
with lipid layer molecular arrangement in bilayer membrane [44].
8. Application of nanoethosomes and transethosomes
Ethosomes and nanoethosomes have enhanced efficiency as compared to liposomes. They give
65% better results in drug delivery as compared to liposomes as they easily crosses the human
skin layers. Few bioactive agents are considered to investigate the efficacy of these vesicular
systems which are described in Tables 3 and 4 [45].
8.1. Transdermal delivery of anti-fungal bioactives
To ascertain the drug delivery efficiency of vesicular carrier system for anti-fugal drugs,
Bhalaria et al. conducted an experiment where they took fluconazole and prepared nano-
ethosomes from them [46]. Then they took that nanoethosomal preparation and checked their
efficacy in cutaneous candidiasis patients. This experiment showed positive results as the
nanoethosomal preparations displayed a better clinical efficiency as compared to liposomal
preparation, hydroethanolic solution and the marketed preparations of same drug. Girhepunje
et al. conducted similar experiments taking ciclopiroxolamine ethosomes. Here he considered
entrapment and optimized size and result of the experiment showed that due to presence of
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Drug Excipients Sophisticated techniques
used
EE (%) Size/PDI Animal
model
Key findings
(1) Anti-fungal drugs
Amphotericin B Soya phosphatidylcholine,
propylene glycol, ethanol
Transmission electron
microscopy (TEM), confocal
laser scanning microscopy
(CLSM)
71.56 218.4  2.9 nm/
0.451  0.03
— Drug loaded nanoethosomes showed
high drug entrapment, greater
penetration power, and high stability
compared to liposomes
Clotrimazole Soya phosphatidyl choline
(Phospholipon 90 H), ethanol
TEM, atomic force
microscopy (AFM), FT-IR
spectroscopy
68.73  1.4 %/132  9.5 nm/
0.027  0.011
Sprague
Dawley
rats
Nanoethosomes showed high drug
entrapment, enhanced transdermal
permeation flux, and in-vitro anti-fungal
activity compared to ultradeformable
liposomes; along with high zone of
inhibition compared to marketed
formulation
Clotrimazole Cavamax (W6, W7, and W8),
propylene glycol, ethanol,
triethanolamine, iso-
propylmyristate
TEM, CLSM 98.42  0.15 202.8  4.8 nm/
0.113  0.024
Wistar
albino
rats
Cavamax W7 composite ethosomal gel
showed high drug permeation flux,
deeper penetration in epidermis and high
anti-fungal activity against Candida
albicans and Aspergillus niger compared to
normal ethosomal gel
Griseofulvin Phospholipon 90G, Carbopol
980 NF, ethanol
TEM, fluorescence
microscopy, reverse phase
HPLC
72.94  0.80 148.5  0.48 nm/
0.203
Laca
mice
Griseofulvin-loaded Ethosomes
completely cured fungal infection in
guinea pigs in 8 days upon twice daily
topical applications
(2) Cardiovascular drugs
Minoxidil Phospholipon 90, ethanol,
phosphotungstic
TEM, CLSM, HPLC, 31P-
NMR
83  6 153  15 nm/– Male
albino
mice
Prepared nanoethosomal formulation at
2% phosphatidylcholine and 30% ethanol
showed rapid enhancement in
transdermal permeability of compared
hydroethanolic or phospholipid ethanolic
solution of minoxidil
Valsartan Phospholipon 90G, ethanol,
cholesterol
TEM, CLSM, HPLC 89.34  2.54 209  15 nm/– Wistar
albino
rats
Results of study showed penetration of
nanoethosomes in deeper skin layers
compared to conventional liposomes and
3.03 times increase in bioavailability
compared to oral suspension of valsartan
Nanomedicines
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Drug Excipients Sophisticated techniques
used
EE (%) Size/PDI Animal
model
Key findings
(3) Antiviral drugs
Lopinavir Phospholipon 90 H, cholesterol,
ethanol
TEM, fluorescence
microscopy, HPLC
79.6  4.1 112.8  12.4 nm/
0.131  0.008
Wistar
rats
Fluorescence study revealed better
disposition of ethosomal carrier in rat
skin compared to niosomes; but, in-vivo
extent of absorption was high in case of
niosomal carrier system
Hepatitis B
surface antigen-
Soya phosphatidylcholine, Span
80, ethanol
Flow-cytometric analysis,
spectral bioimaging
— — — Nanoethosomes showed high
internalizing capacity and
immunogenicity compared to elastic
liposomes following transcutaneous
route
Indinavir Soya phosphatidylcholine,
ethanol
TEM, SEM, HPLC 96.71  1.4 147  4.5 nm/
0.12  0.03
Human
cadaver
skin
Nanoethosomes showed greater
permeation of drug through human
cadaver skin along with shortest lag time
compared to conventional liposomes
(4) Anti-inflammatory drugs
Triptolide Dipalmitoylphosphatidyl
choline, cholesterol, ethanol
HPLC 98.8  4.7 123.1  8.6 nm/
0.335
Sprague
Dawley
rats
Nanoethosomal formulation showed
highest in-vitro accumulation of
Triptolide in skin and significant
reduction in erythema in-vivo in rat
model
Aceclofenac Soybean phosphatidylcholine,
isopropyl alcohol
Scanning electron
microscopy (SEM)
95.7 0.696 μm/– — Nanoethosomal formulation showed
very high transdermal flux and high
stability for 45 days compared to an
ethanolic drug solution
Diclofenac
sodium
Soya lecithin, cholesterol,
ethanol
Photon correlation
spectroscopy
51.72  4.36 202  20.6 nm/
0.34
Sprague
Dawley
rats
Nanoethosomal formulation showed
high permeation through rat skin and
permeability coefficient of
nanoethosomes was 15-folds higher than
conventional liposomes
Ketoprofen Soya phosphatidyl choline,
cholesterol, ethanol
TEM, CLSM, HPLC 78.7  4.9 120.3  6.1 nm/– Adult
Chinese
Nanoethosomal formulation showed
high transdermal flux and high in-vitro
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Drug Excipients Sophisticated techniques
used
EE (%) Size/PDI Animal
model
Key findings
female
skin
penetration compared to hydroethanolic
solution of drug through human skin
(5) Miscellaneous bioactive materials
Glimepiride Phospholipon 90 G, propylene
glycol, cholesterol, ethanol
SEM, TEM, HPLC, CLSM 99.89% 93 nm/– Male
Wistar
rats
In-vivo study of ethosomes in human
volunteers showed extended drug release
behavior and lower maximum drug
plasma level when used in the form of
transdermal films
Apigenin Lipoid S 75, propylene glycol,
ethanol
TEM, HPLC 85.21  3.97 36.61  1.78 nm/– Sprague
Dawley
rats
Apigenin loaded nanoethosomes showed
effective reduction of cyclooxygenase-2
levels in mouse skin inflammation
induced by ultraviolet B (UVB) light
compared to liposomes/deformable
liposomes
Tacrolimus Lipoid S 100, absolute ethanol TEM, HPLC 79.8  1.6 76.3  0.5 nm/
0.26  0.01
BALB/c
mice
Tacrolimus loaded nanoethosomes
showed higher encapsulation efficiency,
lower vesicle size, and skin penetration
compared to conventional liposomes
with cholesterol
Paclitaxel Phospholipon 90G, absolute HPLC, TEM, cell cycle
analysis and apoptotic
determination
82.00  1.78 240.0  61.48 nm/
0.145  0.047
Adult
human
skin
Paclitaxel loaded nanoethosomes showed
improved penetration capacity through
stratum corneum epidermal membrane
model and increased antiproliferative
activity in squamous cell carcinoma
model as compared to the free drug
solution
5–
Aminolevulinic
acid (ALA)
Phosphatidyl ethanolamine,
ethanol
Colorimetry, CLSM, HPLC — — — CLSM study showed depth of
penetration of nanoethosomes up to
80 μm in murine skin and penetration
studies showed 26-folds increase in
transdermal flux of nanoethosomes
compared to plain ALA solution
Table 3. Applications of nanoethosomes for transdermal delivery of various classes of drugs.
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45% ethanol there is higher level of entrapment and vesicles formed are of optimized size [47].
Table 3 provides information regarding few of the researches that has been conducted on
nanoethosomal drug delivery of anti-fungal class of drug.
8.2. Transdermal delivery of anti-inflammatory bioactives
To have an idea about the efficacy of ethosomal preparation in delivering anti-inflammatory
drug Paolino et al. conducted an investigative experiment on few human volunteers taking
ethosomes entrapped with ammonium glycyrrhizinate. The ethosomal preparation which was
having an ethanol content about 45% and having a lesser lecithin content gave better results
both in in-vitro and in-vivo consideration. In case of in vitro it showed enhanced percutaneous
Drug Excipients Sophisticated
Techniques
used
EE (%) Size/PDI Animal
model
Key findings
Voriconazole Lipoid S100,
cholesterol,
Tween80,
taurocholic
acid sodium,
ethanol
TEM, HPLC 96.6  2.7 191.9  41.5 nm/– Male
albino
mice
Prepared transethosomes
showed high elasticity,
high in-vitro skin
permeation, and high in-
vivo skin deposition of
voriconazole compared
to nanoethosomes and
conventional liposomes
Ketorolac
tromethamine
Phospholipon
90G, sodium
deoxycholate,
propylene
glycol, ethanol
TEM, FT-IR 82.08  4.5%/ 180  70 nm/– Male
albino
rats
Transethosomes showed
3-fold more elasticity
compared to ethosomes
and transethosomal gel 3-
fold increase in
transdermal flux
compared to
conventional ethosomes
Vitamin E Soybean
phosphatidyl
choline,
sodium
cholate,
ethanol
TEM, HPLC 76.689 
2.942
154.73  1.89 nm/
0.428  0.020
Pig ear
skin
For transdermal flux and
stability, order obtained
was: transethosomes
(TE) > ethosomes
(E) ≥ transferosomes (T)
for vitamin E
Caffeine Soybean
phosphatidyl
choline,
Sodium
cholate,
ethanol
TEM, HPLC 3.376  0.812 116.60  2.25 nm/
0.133  0.015
Pig ear
skin
For transdermal flux and
stability, order obtained
was: transethosomes
(TE) > ethosomes
(E) ≥ transferosomes (T)
for caffeine
Griseofulvin Phospholipon
90G, Carbopol
980 NF,
TEM, HPLC
fluorescence
microscopy,
reverse phase
72.94  0.80 148.5  0.48 nm/
0.203
Laca
mice
Griseofulvin-loaded
ethosomes completely
cured fungal infection in
guinea pigs in 8 days
upon twice daily topical
applications
Table 4. Applications of transethosomes for transdermal delivery of some miscellaneous drugs.
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permeation, better tolerability of skin, and in vivo consideration showed enhanced anti-
inflammatory activity in human volunteers. Nanoethosomes being smaller in size and having
higher content of ethanol displayed better entrapment efficiency. Brief information has been
given in Table 3 regarding transdermal delivery of anti-inflammatory drug [48].
8.3. Transport of drug with action on cardiovascular system
To ascertain the extent of delivery of cardiovascular drug from transdermal system of drug
delivery Touitou et al. investigated the efficiency of nanoethosomes filled with minoxidil. The
nanoethosomes that were prepared with 2% of phosphatidylcholine and 30% of ethanol
displayed a relatively increased permeability when compared with the formulation of
hydroethanolic and phospholipid minoxidil. In another experiment Ahad et al. took valsartan
and investigated the penetration capability of the nanoethosomes containing valsartan in the
skin of Wistar albino rats. The results were amazing as there was increased penetration into
deeper layers of skin when compared with liposomal preparation of same drug and it also
shows increased bioavailability when compared with oral route of administration. In addition
to this Bhosale and Avachat documented an increased antihypertensive action in Wistar albino
rats when given transdermally as compared with oral administration of same [49]. Table 3
shows role of nanoethosomes in antihypertensive drug delivery.
8.4. Transport of bioactive agent with antiviral activity
Nanoethosomes of lamivudine is been prepared by Jain et al. to evaluate the efficacy of
transdermal delivery of antiviral drugs. The nanoethosomal preparation showed 25 times
better penetration of drug through as compared to a simple solution. T-lymphocytes showed
increased uptake ability for nanoethosomes compared to free drug solution [33]. Few more
examples regarding transdermal drug delivery of antiviral drug is given in Table 3.
8.5. Delivery of miscellaneous bioactives
Nanoethosomes were compared with hydroethanolic and liposomal preparation, for that
Dayan & Touitou prepared a nanoethosomes that was loaded with trihexyphenidyl HCl and
result that came were really great as nanoethosomes showed better transdermal permeation
than both the above mentioned preparation [50]. The penetration of nanoethosomes was
deeper as compared to conventional liposomes. Dubey et al. studied melatonin loaded
nanoethosomes in cadaver skin of human and are compared with liposomes. Result showed
high mobility of drug through skin in case of nanoethosomes. Table 3 provides brief informa-
tion about nanoethosomes for delivery of various types of drugs [35].
9. Patent related to nanoethosomes
First patent related to nanoethosomes granted in 1986 by Prof. Elka Touitou of Hebrew
University School of Pharmacy, Jerusalem. Descriptions of few patents regarding transdermal
drug delivery of nanoethosomes are given in Table 5.
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Title of patent Brief description Inventors Patent number
Ethosome preparation of male
hormone medicaments and its
preparation method
This invention describes the
preparation technique of ethosomes
loaded with male hormone used to
treat various male diseases like male
sterility, endocrine erectile
dysfunction, and male climacteric
syndrome
Guan Yan Min,
MengShu, Li Jianxin,
Dan
CN102406605 A
Progesterone ethosome, and
preparation method and application
there of
This invention describes a method of
encapsulation of progesterone (0.1–
1%) in ethosomes for treatment of
secondary amenorrhea, dysfunctional
bleeding, and premenstrual
syndrome
Zhang Shu, Deng Hong,
Lin Huaqing, Zhang
Xiaoling
CN102397255 B
Transdermal composition for
treating pain
This invention describes ethosomal
composition for transdermal delivery
for treatment of pain; the present
invention can be used to treat
different type of pain like muscular,
nociceptive and neuropathic in origin
Moheb Maalawy WO2015123750
A1
Preparation method of lidocaine
ethosome
This invention discloses a method of
preparation of lidocaine ethosomes
using lecithin and ethanol as major
constituent; prepared ethosomes
showed entrapment up to 80.93% and
good skin compatibility
Liang Ju, Wu Wenlan,
Li, Miao Juan, Wei
Xuefeng, Chen Shan,
Wang Xiaotaro
CN102688194 B
Daptomycin ethosome preparation This invention describes preparation
method of daptomycin ethosomes
using 1 mg daptomycin, 10–20 mg
lecithin, 0.6–0.8 ml ethanol, and
balance of water; the ethosomes show
low preparation cost and high
stability
Lee Chong, Liu Ha,
YanqiKun, Wang
Xiaoying, Chen Po
CN103006562 B
Phenasteride gel preparation This invention discloses preparation
method of phenasteroid using 0.5–4%
phospholipid and their dispersion in
carbomer (0.25–1.5%) gel for topical
application
Liang Wen- right,
RaoYuefeng
CN1555804 A
Bullatacin ethosome gel and
preparation method thereof
This invention describes method of
preparation of ethosomal gel using
Brad he octyl, phospholipid, low
molecular weight alcohol, cholesterol,
stabilizer, and antioxidant; size of
ethosome is 30–400 nm
Tan Jianping, Jiang
Lixin, often calm, Zhou
Zhiwen
CN102552147 B
Acyclovir ethosome and
preparation method thereof
This invention discloses acyclovir
loaded ethosomes with improved
stability by addition of polyethylene
glycol or chitosan for percutaneous
administration
Wuxue Wen, Xiong Yan CN102133183 B
Ethosomes preparation of
antimycotics pharmaceutical and
method for preparing the same
This invention discloses an ethosomal
preparation loaded with anti-fungal
drug containing 1–8% phospholipid,
20–45% ethanol, and 40.9–78.9% of
water
Liu Liping, Li Yimin,
ShenMing- high, six
Jiang Hu, Yang Jin
CN101273971 A
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10. Conclusion
The work presented here is an overview on one of the current novel drug delivery device
named as vesicular carrier. For researchers in the field of novel drug delivery vesicular
carrier has become an area of interest which makes the future of vesicular carrier application
bright in field of therapeutics and drug delivery. As vesicular carrier has an inert ability to
better factors like solubility, penetration, uptake as well as it provides a better carrier facility
to ensure the stability of various types of drugs and proteins, this makes it bankable delivery
system of bioactive agents. In addition to this vesicular system is compatible with both
hydrophilic as well as hydrophobic drug and easy encapsulate them. It also encapsulate
herbal bio agent and ensure their stability. These said characteristics makes vesicular carrier
system a promising option in the field pharmaceutical nanotechnology and herbal medi-
cines. Vesicular carrier system has few thing as drawbacks like instability, relatively smaller
short shelf life or difficulty to reach the target. All the drawbacks can be overcome by few
techniques like providing appropriate storage condition to maintain stability, giving a poly-
meric coating to the preparation or conjugating the preparation with suitable ligands.
To ascertain or assess the vesicular carrier stability and acceptability said parameters can
be employed.
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Title of patent Brief description Inventors Patent number
Clotrimazole ethosomes for
preventing and curing weaning
rabbit dermatomycosis and
preparation method thereof
This invention describes the
composition and method of
preparation of ethosomes loaded
with clotrimazole having 3% of
lecithin and 1% of clotrimazole by
weight
Liu Man, Mou special,
Liming Yong
CN104873465 A
Table 5. Description of patents related to nanoethosomes for transdermal drug delivery.
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